LifeSci Capital Initiates Coverage of Addex Therapeutics

Developing allosteric modulators to treat a wide range of CNS disorders; Report Available here: www.lifescicapital.com/equity-research/addex/

NEW YORK, NY / ACCESSWIRE / July 19, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Addex Therapeutics (SIX: ADXN.SW), a biotechnology company developing novel allosteric modulators with therapeutic potential. The Company’s lead program is dipraglurant for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (PD). Across all PD patients, the overall 5-year risk of developing LID is roughly 40%. However, by 15 years after diagnosis, greater than 90% of PD patients have developed LID.

Although levodopa is the most commonly prescribed treatment for PD, its long-term use is associated with the emergence of disabling motor fluctuations and dyskinesias. Dipraglurant is a small molecule negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5) that dampens glutamatergic signaling in the basal ganglia thought to underlie dyskinesias. Addex has completed a Phase IIa study evaluating dipraglurant with the support of a grant from the Michael J. Fox Foundation and plans to launch a pivotal Phase III study in the second half of 2017.

In a 33 page Initiation Report, LifeSci Capital explains the Company’s development strategy, the large market opportunity due to high rates of LID, and the Company’s broad pipeline of allosteric modulators targeting CNS indications.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Addex Therapeutics as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 442591